Quality Measures Developed For Childhood Cancer Care Systems

Published Jun 17, 2013
Toronto, ON, Canada - Researchers at Pediatric Oncology Group of Ontario (POGO) and McMaster University have developed measures of the quality of childhood cancer care delivery systems. These measures will be used to evaluate the performance of the childhood cancer system in Ontario and inform increased system improvements and accountability. Twenty indicators were selected and prioritized for phased implementation in Ontario, with a high-level of consensus from stakeholders. Twin articles, “Measuring the Quality of a Childhood Cancer Care Delivery System: Quality Indicator Development” and “Measuring the Quality of a Childhood Cancer Care Delivery System: Assessing Stakeholder Agreement,” published in Value in Health, in June 2013, describe how the team of decision-makers, expert clinicians and methodologists, developed a set of evidence and consensus-based quality indicators; selected a quality assessment framework; and established consensus amongst stakeholders. The indicators span the continuum of childhood cancer care, from diagnosis and treatment to survivorship, and reflect seven quality dimensions of the Cancer System Quality Index framework adapted for Ontario’s childhood cancer system, including safety, effectiveness, accessibility, responsiveness, equity, integration, and efficiency. The prioritized indicator set is intended to reflect perspectives of key stakeholders and will enable examination of service delivery to patients of varying levels of complexity of care at various stages of the continuum. Care of children with cancer is complex, due to the severity of illness, intensity and duration of treatment, and immediate and long-term consequences. This project creates a balanced scorecard to evaluate a childhood cancer system, articulates methods used to develop quality indicators and stakeholder consensus, and provides clear definitions of selected measures. “This is the first set of quality indicators developed for a childhood cancer system in any jurisdiction internationally,” said Dr. Mark Greenberg, ChB MB, Senior Adviser, Policy and Clinical Affairs at POGO, and co-author of the studies. “Implementation of the 20 quality indicators will lead to the development of benchmarks for optimal service delivery over time and across populations and jurisdictions, and will generate information of interest to health care providers, survivors, families, and policy makers to stimulate and inform quality improvements and health care accountability.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

ISPOR Tackles Health Disparities with New Research Primer

Jan 22, 2025

ISPOR announced today the publication of a report from the ISPOR Health Equity Research Special Interest Group intended to establish key concepts for conducting health equity research that enables investigators to examine—and ultimately reduce—unfair social inequities in health.

Global Expert Panel Releases Good Practices Guidance for Developing or Updating Health Technology Assessment Guidelines

Jan 14, 2025

ISPOR announced today the publication of a tripartite task force report outlining good practices for developing or updating health technology assessment (HTA) guidelines.

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×